Medication Monitor



Generic Name (Trade Name—Company)
Notes
September 5, 2018

Multiple generic names

(Neuroveen, Respitrol, Thyroveev, Compulsin—HelloLife)
FDA alerts consumers of HelloLife’s voluntary recall of Neuroveen, Respitrol, Thyroveev, and Compulsin

HelloLife is initiating a voluntary recall of four different products, Neuroveen, Respitrol, Thyroveev, and Compulsin, within expiry, to the retail and consumer level because of possible microbial contamination. Neuroveen has been tested and found to be contaminated with Staphylococcus saprophyticus and Burkholderia cepacia. Compulsin has been identified as containing Burkholderia cepacia.

Respitrol and Thyroveev are still pending bacterial identification. Each product being recalled is for a single lot that was packaged into 2-ounce amber bottles (see table here) that were manufactured at the King Bio facility in Asheville, NC.

To date, HelloLife has not received any reports of adverse events related to the recalled products.